USPSTF Recommends Hep B Screening for Those at Increased Risk

FDA Reports Rare Cases of Liver Injury, Failure With Hep C Therapies

The U.S. Food and Drug Administration has received reports of rare cases of worsening liver function or liver failure in patients with chronic hepatitis C virus who had moderate-to-severe liver impairment and were treated with Mavyret, Zepatier, or Vosevi, despite these drugs being contraindicated in this group of patients, the agency reported yesterday.

Direct-Acting Antivirals Cut Mortality in Chronic Hepatitis C

For adults with chronic hepatitis C virus infection, direct-acting antivirals are associated with a reduced risk for mortality and hepatocellular carcinoma, according to a study published online Feb. 11 in The Lancet.